Search | Clinical Trials Finder

Conditions: Pulmonary Arterial Hypertension
Interventions: QCC374; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Infliximab; Biological
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 45
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more

Conditions: Lymphedema
Interventions: Manual lymph drainage, Combined physiotherapy, Compression bandaging; Procedure
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: Not listed
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Corneal Swelling
Interventions: etafilcon A, lotrafilcon B, comfilcon A; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deep Vein Thrombosis, DVT
Interventions: Not listed
Lead sponsor: Emergency Medicine Physicians, Nevada; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Breast Cancer, Breast Cancer Treatment Related Lymphedema
Interventions: Juzo Compression Sleeve and Glove, Compression Sleeve Sensor; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Secondary Lymphedema
Interventions: CDT with Negative Pressure, CDT alone; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 30 Years to 90 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: AD 452; Drug
Lead sponsor: Sosei; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 10
States / cities: Clearwater, Florida • Fort Lauderdale, Florida • Ocala, Florida + 7 more

Conditions: Lipedema, Secondary Lymphedema
Interventions: CDT with graded negative pressure; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 14 Years to 90 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: QCC374, Placebo Matching; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoarthritis
Interventions: Diclofenac Sodium gel, 1%, Voltaren® Gel, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 35 Years and older
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 44
States / cities: Mesa, Arizona • Anaheim, California • Canoga Park, California + 32 more

Conditions: Urticaria, Angioedema, Hives, Swelling
Interventions: High Dose Vitamin D3, Low Dose Vitamin D3; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Central Abdominal Bulging
Interventions: LIPO-202, Placebo; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 6
States / cities: Encinitas, California • Manhattan Beach, California • Aventura, Florida + 3 more

Conditions: Bleeding, Bruising Face, Swelling Lips & Face
Interventions: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag; Drug
Lead sponsor: Glasgold Group Plastic Surgery; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Conditions: Breast Edema, Breast Lymphedema, Lymphedema, Breast Cancer, Lymphedema
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Varicose Veins
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Knee Osteoarthritis, Knee Discomfort, Knee Pain Chronic, Knee Swelling Pain
Interventions: Embolization; Device
Lead sponsor: Lucas R. Cusumano, MD; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sleep Related Breathing Disorder, Snoring, Obstructive Sleep Apnea (OSA), Open Bite, Occlusal Changes, Tooth Migration, Posterior Open Bite
Interventions: AM Aligner, Exercise; Device · Behavioral
Lead sponsor: Isabel Moreno Hay; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Abdomen Hernia
Interventions: Prevena, Prineo, Traditional; Device · Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Radiculopathy, Herniated Disc, Disc Degeneration
Interventions: Regenexx PL-Disc, Steroid Epidural; Procedure
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions: Dexamethasone; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

RESTART C0168Z05 Rheumatoid Arthritis Study

Massage Therapy for Breast Cancer Treatment-Related Swelling of the Arms

Central Corneal Swelling With Silicone Hydrogel Materials

DVT Ultrasound in the Emergency Department

Early Intervention

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Imaging Biomarkers of Lymphatic Dysfunction

A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

Intravenous Tranexamic Acid During Rhytidectomy

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

The BEACON Trial: Diagnostic Tools for Breast Lymphedema After Treatment for Breast Cancer

Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins

IMAGES: Identifying Metabolic Imaging Association With Genicular Artery Embolization Success

IOA Preventing Occlusal Changes With MAD Use

The Effects of Post-Operative Interventions on Surgical Site Occurrences in AWR

Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy

Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors